In today’s briefing:
- China Healthcare Weekly (Nov.17) – TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross
- 2024 High Conviction Update: Asahi Intecc (7747 JP)- Medical Division Drives Q1 Result
- Glaukos Corporation: Advancement of iDose TR & Market Penetration As A Pivotal Growth Lever! – Major Drivers
- Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers
- How Gilead Sciences’ HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth! – Major Drivers
- McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers
- Novo Nordisk: Global Adoption & Expansion of GLP-1 Therapeutics Driving Our Bullishness! – Major Drivers
- Royalty Pharma Plc: Revolutionizing Biopharma with Synthetic Royalty Funding Innovations! – Major Drivers
China Healthcare Weekly (Nov.17) – TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross
- The new round of national TCM decoction pieces VBP has started. We think the overall price reduction would be relatively mild, and the impact on related TCM enterprises is limited.
- The NHSA will vigorously promote the expansion of TCM VBP, which is another challenge for TCM injections. But the impact on exclusive TCM varieties and innovative TCM injections is smaller.
- CR Boya has completed the acquisition of 100% equity of Green Cross and has included it in the scope of consolidated financial statements starting from November. Future M&As will continue.
2024 High Conviction Update: Asahi Intecc (7747 JP)- Medical Division Drives Q1 Result
- Asahi Intecc (7747 JP) recorded 9% YoY revenue growth to ¥31B in Q1FY25. Revenue growth is attributable to the continued strong trajectory of medical division, which reported 10% YoY growth.
- Strong rebound in China is key highlight for medical division performance. Revenue from China increased by a whopping 36% YoY and 44% QoQ to a record high of ¥9.3B.
- Despite a better-than-expected Q1FY25, the company maintains full-year FY25 guidance, due to external factors such as currency movements as well as uncertainties in trends for net sales, productivity, and expenditure.
Glaukos Corporation: Advancement of iDose TR & Market Penetration As A Pivotal Growth Lever! – Major Drivers
- Glaukos Corporation’s third quarter 2024 financial results highlighted a period of notable growth driven by strategic product developments and an expanding market presence.
- The company achieved record consolidated net sales of $96.7 million, representing a 24% increase from the previous year.
- This performance prompted Glaukos to revise its full-year 2024 net sales guidance upwards to $377 million to $379 million, reflecting optimism about continued growth.
Jazz Pharmaceuticals Plc: Its Efforts Towards Zepzelca Frontline Therapy Expansion & Other Major Drivers
- Jazz Pharmaceuticals recently reported its third quarter 2024 financial results, reflecting a period of noteworthy commercial growth and strategic progression, particularly in its neuroscience and oncology business units.
- The company recorded a total revenue exceeding $1.05 billion, a 9% increase compared to the same quarter in 2023.
- This growth was primarily fueled by the continued strong performance of Xywav and Epidiolex in the neuroscience segment, with both products achieving record quarterly sales and double-digit year-over-year growth.
How Gilead Sciences’ HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth! – Major Drivers
- Gilead Sciences, Inc. reported a strong financial performance for the third quarter of 2024, showcasing robust growth across its main therapeutic areas, including HIV, oncology, and liver disease.
- This growth has allowed Gilead to increase its full-year guidance for key financial metrics such as revenue, operating income, and earnings per share, underscoring its effective commercial and operational execution.
- Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
McKesson Corporation: Will Its Cost Optimization & Operational Efficiencies Help Alter The Playing Field? – Major Drivers
- McKesson Corporation’s second quarter fiscal 2025 results present a multidimensional view of the company’s current financial standing and future prospects.
- With reported record revenues of $93.7 billion, McKesson demonstrated a robust 21% year-over-year increase, driven significantly by the U.S. Pharmaceutical segment.
- This sector alone witnessed a 23% revenue boost, underscored by the onboarding of a new strategic partner and broadened specialty product distribution.
Novo Nordisk: Global Adoption & Expansion of GLP-1 Therapeutics Driving Our Bullishness! – Major Drivers
- Novo Nordisk recently presented its third-quarter financial results, showcasing significant growth and strategic developments within the company.
- The key highlights from the call indicate robust expansion across various segments, particularly driven by the strong performance of its diabetes and obesity treatments, including notable products like Ozempic and Wegovy.
- The company reported an impressive 24% increase in sales alongside a 22% rise in operating profit for the first nine months of the fiscal year.
Royalty Pharma Plc: Revolutionizing Biopharma with Synthetic Royalty Funding Innovations! – Major Drivers
- Royalty Pharma, a leading investor in biopharmaceutical royalties, recently reported its third-quarter 2024 results.
- The company highlighted strong business momentum, driven by its diverse portfolio of more than 35 commercial products.
- Financially, Royalty Pharma achieved a 15% growth in both Portfolio Receipts and Royalty Receipts.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
